Zacks: Metabolix, Inc. (YTEN) Given Consensus Recommendation of “” by Analysts
Shares of Metabolix, Inc. (NASDAQ:YTEN) have been assigned an average broker rating score of 0.00 () from the zero brokers that cover the company, Zacks Investment Research reports.
Zacks has also assigned Metabolix an industry rank of 180 out of 265 based on the ratings given to related companies.
TRADEMARK VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/01/zacks-metabolix-inc-yten-given-consensus-recommendation-of-by-analysts.html.
Metabolix (YTEN) traded up 2.23% during trading on Tuesday, hitting $2.75. 11,410 shares of the stock traded hands. The company’s 50 day moving average price is $2.68 and its 200-day moving average price is $1.98. The stock’s market cap is $9.50 million. Metabolix has a 52-week low of $2.18 and a 52-week high of $9.30.
Metabolix (NASDAQ:YTEN) last posted its quarterly earnings results on Thursday, August 10th. The specialty chemicals company reported ($0.96) earnings per share for the quarter. Metabolix had a negative return on equity of 145.04% and a negative net margin of 190.57%. The company had revenue of $0.29 million for the quarter.
A hedge fund recently bought a new stake in Metabolix stock. Birchview Capital LP acquired a new position in shares of Metabolix, Inc. (NASDAQ:YTEN) during the first quarter, according to its most recent filing with the SEC. The firm acquired 2,263,166 shares of the specialty chemicals company’s stock, valued at approximately $807,000. Metabolix accounts for about 0.4% of Birchview Capital LP’s portfolio, making the stock its 16th largest position. Birchview Capital LP owned approximately 7.97% of Metabolix as of its most recent filing with the SEC. 9.21% of the stock is currently owned by institutional investors and hedge funds.
Yield10 Bioscience, Inc, formerly Metabolix, Inc, is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Metabolix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metabolix Inc. and related stocks with our FREE daily email newsletter.